ODI Pharma aktie (ODI) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Kom igång: Så börjar du spara i fonder 2025 – bästa tipsen för att komma igång (stor guide)

Pressmeddelanden från ODI Pharma

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

ODI Pharma AB announces last day of trading in BTA

ODI Pharma AB’s ("ODI" or the "Company") preferential issue of shares, with a subscription period ending on December 10, 2024, has now been ...

Cision • 19 Dec 13:30

Flagging notification

ODI Pharma AB ("ODI Pharma") hereby informs that the current CEO, Derek Simmross, did not subscribe to his pro-rata in the completed rights ...

Cision • 13 Dec 11:30

ODI Pharma AB publishes outcome of rights issue

The subscription period in ODI Pharma AB’s ("ODI" or the "Company") issue of shares with preferential right (the “Rights Issue”) ended on De...

Cision • 11 Dec 15:55

ODI Pharma achieved market share targets in 2024 and increases its targets for 2025. Positioned for growth as Poland's medical cannabis market expands.

ODI Pharma AB ("ODI" or the "Company") provides an update on Poland’s expanding medical cannabis market, which remains an important focus of...

Cision • 04 Dec 13:30

ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2023/2024

Styrelsen och verkställande direktören för ODI Pharma AB ("ODI Pharma") publicerar härmed årsredovisningen för räkenskapsåret 2023/2024.

Cision • 02 Dec 07:45

ODI Pharma AB publishes the annual report for the fiscal year 2023/2024

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal yea...

Cision • 02 Dec 07:45

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma måndagen den 30 december 2024 kl.

Cision • 27 Nov 11:30

Notice to Annual General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Monday, 30th of December 2...

Cision • 27 Nov 11:30

The subscription period in ODI Pharma AB’s preferential rights issue commences today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 26 Nov 07:50

ODI Pharma AB publishes memorandum prior to preferential rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 25 Nov 11:45

Publication of interim report Q1 2024/2025

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2024 – September 2024.

Cision • 22 Nov 15:31

ODI Pharma moves the AGM and postpones the publication of Annual Report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby hereby announces that the Company, due to administrative reasons, chooses to move the Annual G...

Cision • 22 Nov 15:30

Report from the Extraordinary General Meeting on 19 November in ODI Pharma AB (publ)

Today, 19 November 2024, an Extraordinary General Meeting was held in ODI Pharma AB (publ), reg.

Cision • 19 Nov 16:00

Kommuniké från extra bolagsstämma den 19 november i ODI Pharma AB (publ)

Idag, den 19 november 2024, hölls extra bolagsstämma i ODI Pharma AB (publ), org.

Cision • 19 Nov 16:00

Updated Notice of Annual General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby summoned to the Annual General Meeting on Friday, December 13, 2024, at 10...

Cision • 13 Nov 12:30

Uppdaterad kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223-1392, kallas härmed till årsstämma fredagen den 13 december 2024 kl.

Cision • 13 Nov 12:30

ODI Pharma appoints new CEO

The board of ODI Pharma AB (“ODI” or the “Company”) has today appointed Jan-Mark Edewaard as the new CEO of ODI as of January 1, 2025.

Cision • 12 Nov 11:41

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma fredagen den 13 december 2024 kl.

Cision • 12 Nov 11:40

Notice to Annual General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 13th of December 2...

Cision • 12 Nov 11:40

Notice of Extraordinary General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby invited to an Extraordinary General Meeting to be held on Tuesday 19 Novem...

Cision • 30 Oct 15:42

Kallelse till extra bolagsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223-1392, kallas härmed till extra bolagsstämma tisdagen den 19 november 2024 kl.

Cision • 30 Oct 15:42

Proposal for change in the Board of Directors of ODI Pharma AB

Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting on N...

Cision • 30 Oct 15:41

ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 30 Oct 15:40

ODI Pharma AB announces strategic market entry with initial shipment to Switzerland

ODI Pharma AB (“ODI” or the “Company”) is pleased to announce the first delivery of cannabis products to the leading medical cannabis provid...

Cision • 25 Jun 18:35

ODI Pharma AB: Publication of interim report Q3 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024.

Cision • 30 May 11:45

Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024

ODI Pharma AB (“ODI” or the “Company”) announces today that the preliminary financial results for the third quarter of fiscal year 2023/2024...

Cision • 02 May 13:30

Kommuniké från årsstämma i ODI Pharma AB (publ)

Idag den 15 december 2023 hölls årsstämma i ODI Pharma AB (publ).

Cision • 15 Dec 2023 11:15

Announcement from the Annual General Meeting in ODI Pharma AB (publ)

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish.

Cision • 15 Dec 2023 11:15

ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek

ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol.

Cision • 06 Dec 2023 13:53

Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023

The correction refers to the completion of the auditor's remark and ODI Pharma's comment which is now included in the press release.

Cision • 27 Nov 2023 13:17

Rättelse: ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023

Rättelsen avser komplettering av revisorns anmärkning och ODI Pharmas kommentar som nu finns inkluderat i pressmeddelandet.

Cision • 27 Nov 2023 13:17

ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023

Styrelsen och verkställande direktören för ODI Pharma AB (”ODI Pharma”) publicerar härmed årsredovisningen för räkenskapsåret 2022/2023.

Cision • 24 Nov 2023 17:45

ODI Pharma AB publishes the annual report for the fiscal year 2022/2023

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal yea...

Cision • 24 Nov 2023 17:45

ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023

ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for the first quarter of 2023/2024 and the annu...

Cision • 23 Nov 2023 19:45

Notice to Annual General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 15th of December 2...

Cision • 13 Nov 2023 14:35

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma fredagen den 15 december 2023 kl.

Cision • 13 Nov 2023 14:35

ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2022 – June 2023.

Cision • 24 Aug 2023 19:00

ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has entered through its Polish subsidiary into a collaboration agre...

Cision • 07 Aug 2023 11:00

ODI Pharma AB receives loan financing of EUR 350,000

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has secured loan financing of EUR 350,000 from an external internat...

Cision • 01 Jun 2023 10:44

ODI Pharma AB: Publication of interim report report Q3 2022/2023

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2022 – March 2023.

Cision • 25 May 2023 18:06

ODI Pharma AB: Publication of half-year report 2022/2023

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2022.

Cision • 23 Feb 2023 17:47

ODI Pharma receives approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market

ODI Pharma AB (“ODI” or the “the Company”) announces today that the Company has received approval from the Office for Registration of  Medic...

Cision • 24 Jan 2023 13:57

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma fredagen den 16 december 2022 kl.

Cision • 15 Nov 2022 10:12

Notice to Annual General Meeting in ODI Pharma AB (publ)

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish.

Cision • 15 Nov 2022 10:12

ODI Pharma AB: Publication of year-end report for the fiscal year 2021/2022

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2021 – June 2022.

Cision • 25 Aug 2022 19:00

Correction: ODI Pharma AB: Publication of half-year report 2021

Correction: ODI Pharma hereby discloses a revised half-year report for the period July – December 2021.

Cision • 25 Feb 2022 21:33

ODI Pharma AB: Publication of half-year report 2021

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2021.

Cision • 24 Feb 2022 19:47

Announcement from the Annual General Meeting in ODI Pharma AB (publ)

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish.

Cision • 13 Dec 2021 11:19

Kommuniké från årsstämma i ODI Pharma AB (publ)

Idag den 13 december 2021 hölls årsstämma i ODI Pharma AB (publ).

Cision • 13 Dec 2021 11:13

ODI Pharma AB: Publication of interim report for the first quarter 2021/2022

ODI Pharma AB (“ODI Pharma” or the “Company”) hereby publishes its interim report concerning the period July 2021 – September 2021.

Cision • 25 Nov 2021 17:10

ODI Pharma AB publishes the annual report for the fiscal year 2020/2021

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal yea...

Cision • 18 Nov 2021 16:18

Notice to Annual General Meeting in ODI Pharma AB (publ)

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish.

Cision • 09 Nov 2021 16:20

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma måndagen den 13 december 2021 kl.

Cision • 09 Nov 2021 16:20

ODI Pharma AB announces the date of official launch of kandol.

ODI Pharma AB (“ODI” or the “Company”) hereby announces that kandol.

Cision • 28 Sep 2021 14:43

ODI Pharma AB: Publication of year-end report for the financial year 2020/2021

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the fourth quarter and financial year 1[st] of July 2020 – 3...

Cision • 26 Aug 2021 18:26

ODI Pharma AB approves the official launch of kandol., an exclusive CBD infused skincare line

ODI Pharma AB (“ODI Pharma” or the “Company”), a producer and representative of finished pharmaceutical cannabis and cosmetics products, now...

Cision • 17 Aug 2021 18:07

ODI Pharma AB: Flagging notification

ODI Pharma AB (“ODI Pharma”) has been informed that Mr.

Cision • 09 Jul 2021 16:24

ODI Pharma AB: Publication of interim report for the third quarter 2020/2021

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its interim report concerning the period July 2020 – March 2021.

Cision • 27 May 2021 18:23

ODI Pharma: Update on progress in “Project Poland” and “Project Skin”

In January 2021 and February 2021, ODI Pharma AB (“ODI” or the “Company”) announced the decision to expand its current business with special...

Cision • 21 Apr 2021 18:38

ODI Pharma AB: Publication of half-year report 2020

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2020.

Cision • 25 Feb 2021 15:15

Kommuniké från årsstämma i ODI Pharma AB (publ)

Idag den 14 december 2020, hölls årsstämma i ODI Pharma AB (publ).

Cision • 14 Dec 2020 12:23

ODI Pharma AB publishes the annual report for the fiscal year 2019/2020

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI”) hereby publish the annual report of the fiscal year 2019/202...

Cision • 19 Nov 2020 12:15

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma måndagen den 14 december 2020 kl.

Cision • 11 Nov 2020 13:35

ODI Pharma AB: Publication of year-end report

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its year-end report for the period July 2019 – June 2020.

Cision • 27 Aug 2020 18:33

Idag inleds handeln i ODI Pharmas aktier på Spotlight Stock Market

Idag, den 23 januari 2020, inleds handeln i ODI Pharma AB:s (”ODI Pharma” eller ”Bolaget”) aktier på Spotlight Stock Market.

Cision • 23 Jan 2020 08:30

Slutlig registrering av ODI Pharmas nyemission genomförd

Som kommunicerats tidigare idag har ODI Pharma AB:s (“ODI Pharma” eller “Bolaget”) nyligen genomförda nyemission delregistrerats på Bolagsve...

Cision • 20 Jan 2020 15:08

Korrigering-Delregistrering av ODI Pharmas nyemission genomförd

ODI Pharma AB:s (“ODI Pharma” eller “Bolaget”) nyemission övertecknades kraftigt och Bolaget kommer genom nyemissionen att tillföras cirka 2...

Cision • 20 Jan 2020 12:23

Delregistrering av ODI Pharmas nyemission genomförd

ODI Pharma AB:s (“ODI Pharma” eller “Bolaget”) nyemission övertecknades kraftigt och Bolaget kommer genom nyemissionen att tillföras cirka 2...

Cision • 20 Jan 2020 11:11

ODI Pharmas nyemission inför notering kraftigt övertecknad

Teckningstiden i ODI Pharma AB:s (“ODI Pharma” eller “Bolaget”) nyemission inför notering på Spotlight Stock Market avslutades den 30 decemb...

Cision • 03 Jan 2020 10:23

ODI Pharma har godkänts för notering på Spotlight Stock Market – idag inleds teckningstiden i nyemissionen

ODI Pharma AB (“ODI Pharma” eller “Bolaget”), en tillverkare av färdiga medicinska cannabisprodukter, meddelar idag att Bolaget godkänts för...

Cision • 16 Dec 2019 09:55